title: In vivo pharmacology of a novel AT1 selective angiotensin II receptor antagonist, MK-996.
abstract: MK-996, N-(4'-(5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridin-3-yl- methyl)1,1'-biphenyl-2-yl)-sulfonylbenzamide, is a potent, orally active, highly selective, nonpeptide angiotensin II (AII) receptor antagonist. MK-996 prevents the pressor response to intravenous AII in the conscious rat, dog, and rhesus monkey (ED50, mg/kg; oral/intravenous = 0.067/0.014, 0.035/0.017, and 0.1/0.036, respectively). In the anesthetized chimpanzee, MK-996 (1 mg/kg, iv) produces 100% (peak) inhibition of the AII pressor response and is still active (52%) at 24 h. To our knowledge this pharmacologic profile in the rat, dog, rhesus monkey, and chimpanzee presents the least species variability of any AII receptor antagonist yet described. Responses to methoxamine and arginine vasopressin are not affected by MK-996. In aortic coarcted (high renin) rats, MK-996 (3 mg/kg, by mouth) reduces blood pressure to normotensive (< 120 mm Hg) levels without reflex tachycardia. This dose of MK-996 reduces blood pressure to approximately the same level as both losartan (3 mg/kg, by mouth) and enalapril (3 mg/kg, by mouth) in this model. The duration of antihypertensive activity of MK-996 is similar to enalapril and shorter than losartan at the doses tested. Additionally, in the rat MK-996 does not potentiate the vasodepressor response to bradykinin and completely prevents the ability of AII to stimulate an increase in plasma levels of aldosterone. Therefore, MK-996 is a potent, orally active, nonpeptide AII receptor antagonist with a long duration of action, little species variability, and anti-hypertensive activity.
authors.affiliation: Department of Cardiovascular Pharmacology, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.
authors.forename: S D
authors.initials: SD
authors.lastname: Kivlighn
authors.forename: G J
authors.initials: GJ
authors.lastname: Zingaro
authors.forename: R A
authors.initials: RA
authors.lastname: Gabel
authors.forename: T P
authors.initials: TP
authors.lastname: Broten
authors.forename: T W
authors.initials: TW
authors.lastname: Schorn
authors.forename: L W
authors.initials: LW
authors.lastname: Schaffer
authors.forename: E M
authors.initials: EM
authors.lastname: Naylor
authors.forename: P K
authors.initials: PK
authors.lastname: Chakravarty
authors.forename: A A
authors.initials: AA
authors.lastname: Patchett
authors.forename: W J
authors.initials: WJ
authors.lastname: Greenlee
mesh_terms: D000284:Administration, Oral; D000450:Aldosterone / Q000097:blood; D000804:Angiotensin II / Q000037:antagonists & inhibitors; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001713:Biphenyl Compounds / Q000494:pharmacology; D001920:Bradykinin / Q000494:pharmacology; D004285:Dogs; D004656:Enalapril / Q000494:pharmacology; D005260:Female; D007093:Imidazoles / Q000494:pharmacology*; D007275:Injections, Intravenous; D019808:Losartan; D008253:Macaca mulatta; D008297:Male; D005996:Nitroglycerin / Q000494:pharmacology; D002679:Pan troglodytes; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013777:Tetrazoles / Q000494:pharmacology
chemical_list: D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D007093:Imidazoles; D011725:Pyridines; D013777:Tetrazoles; D000804:Angiotensin II; C090789:MK 996; D000450:Aldosterone; D004656:Enalapril; D005996:Nitroglycerin; D019808:Losartan; D001920:Bradykinin